We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

93 hedge funds and large institutions have $23.6M invested in X4 Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $202K | Put options by funds: $31K

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

4% more funds holding

Funds holding: 89 → 93 (+4)

0.06% less ownership

Funds ownership: 1.95% → 1.89% (-0.06%)

68% less capital invested

Capital invested by funds: $73.2M → $23.6M (-$49.7M)

Holders
93
Holders Change
+4
Holders Change %
+4.49%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
22
Closed
10
Calls
$202K
Puts
$31K
Net Calls
+$171K
Net Calls Change
-$245K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.89M
2
KCM
Kingdon Capital Management
New York
+$947K
3
PFCS
Pale Fire Capital SE
Czech Republic
+$291K
4
BlackRock
BlackRock
New York
+$170K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.2K

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$1.09M
2
GCP
GSA Capital Partners
United Kingdom
-$934K
3
SSA
Schonfeld Strategic Advisors
New York
-$485K
4
UOC
UBS O'Connor
Illinois
-$465K
5
Group One Trading
Group One Trading
Illinois
-$287K
Name Holding Trade Value Shares
Change 		Change in
Stake
CF
51
Cantor Fitzgerald
New York
$9.52K – – –
CWM
52
CIBC World Markets
New York
$8.95K +$10.2K +738 +141%
ProShare Advisors
53
ProShare Advisors
Maryland
$8.73K -$4.78K -347 -22%
HF
54
HRT Financial
New York
$8K +$15.8K +1,149 New
PFSRSONJ
55
Police & Firemen's Retirement System of New Jersey
New Jersey
$7.99K – – –
Wealth Enhancement Advisory Services
56
Wealth Enhancement Advisory Services
Minnesota
$7.88K +$1.41K +102 +10%
PNC Financial Services Group
57
PNC Financial Services Group
Pennsylvania
$7.33K +$413 +30 +3%
TRCT
58
Tower Research Capital (TRC)
New York
$7.22K +$6.86K +498 +96%
Focus Partners Wealth
59
Focus Partners Wealth
Massachusetts
$6.14K +$441 +32 +4%
Commonwealth Equity Services
60
Commonwealth Equity Services
Massachusetts
$6K – – –
VPIM
61
Vanguard Personalized Indexing Management
California
$5.96K +$1.35K +98 +13%
Ameriprise
62
Ameriprise
Minnesota
$5.26K +$83 +6 +0.8%
Mariner
63
Mariner
Kansas
$4.79K +$9.31K +676 New
Renaissance Technologies
64
Renaissance Technologies
New York
$4.75K +$9.23K +670 New
HSBC Holdings
65
HSBC Holdings
United Kingdom
$4.7K +$83 +6 +0.9%
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$4.55K -$4.61K -335 -34%
Legal & General Group
67
Legal & General Group
United Kingdom
$4.4K – – –
PAG
68
Private Advisor Group
New Jersey
$4.37K – – –
BL
69
Bleichroeder LP
New York
$4.22K – – –
WCP
70
Wealthcare Capital Partners
Pennsylvania
$4.22K +$8.2K +595 New
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$4K +$2.15K +156 +44%
LA
72
LexAurum Advisors
Kansas
$3.78K – – –
SIM
73
Seaview Investment Managers
Florida
$3.56K +$6.91K +502 New
Principal Financial Group
74
Principal Financial Group
Iowa
$3.24K -$358 -26 -5%
GS
75
GTS Securities
New York
$2.99K +$5.81K +422 New
1 2
3
4 5

XFOR Hedge Fund Activity: Q1 2025 in Review

93 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2025, worth a combined $23.6M — down 68% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XFOR positions and 10 closed out — a net gain of 5 holders — while 28 added to existing stakes and 22 trimmed.

The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Axa, cutting an estimated $1.09M.

  • 93 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2025, up from 89 in Q4 2024.
  • Funds reported $23.6M of X4 Pharmaceuticals stock for Q1 2025, down 68% quarter-over-quarter.
  • 15 funds opened new X4 Pharmaceuticals positions in Q1 2025 and 10 closed out, a net change of +5 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $1.89M added.
  • The largest X4 Pharmaceuticals seller in Q1 2025 was Axa, an estimated $1.09M sold.

Based on aggregated 13F filings for Q1 2025.